Rhythm Pharmaceuticals, Inc.
RYTM · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -3.29 | 2.91 | -1.35 | -14.14 |
| FCF Yield | -0.41% | -0.58% | -1.21% | -0.55% |
| EV / EBITDA | -137.30 | -97.08 | -74.23 | -89.55 |
| Quality | ||||
| ROIC | -13.09% | -18.68% | -17.11% | -14.88% |
| Gross Margin | 89.28% | 88.57% | 88.85% | 90.95% |
| Cash Conversion Ratio | 0.50 | 0.50 | 0.82 | 0.44 |
| Growth | ||||
| Revenue 3-Year CAGR | 41.16% | 52.85% | 59.69% | 76.57% |
| Free Cash Flow Growth | -14.19% | 42.22% | -114.12% | -227.46% |
| Safety | ||||
| Net Debt / EBITDA | -2.06 | 3.28 | 2.34 | 2.27 |
| Interest Coverage | -11.10 | -7.79 | -8.69 | -7.57 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.29 | 0.19 | 0.20 |
| Cash Conversion Cycle | -165.14 | 95.40 | 231.72 | 192.24 |